UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1375-4
Program Prior Authorization/Notification
Medication Zeposia® (ozanimod)
P&T Approval Date 12/2021, 12/2022, 12/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Zeposia® (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the
treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,
relapsing-remitting disease, and active secondary progressive disease, in adults and moderately
to severely active ulcerative colitis (UC) in adults.
2. Coverage Criteriaa:
A. Multiple Sclerosis
1. Authorization
a. Zeposia will be approved based on the following criterion:
(1) Diagnosis of multiple sclerosis (MS)
Authorization will be issued for 12 months.
B. Ulcerative Colitis
1. Initial Authorization
a. Zeposia will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) Patient is not receiving Zeposia in combination with a targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz),
Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib),
Simponi (golimumab), Skyrizi (risankizumab), Stelara (ustekinumab),
Tremfya (guselkumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Zeposia will be approved based on both of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
1
(1) Documentation of positive clinical response to Zeposia therapy
-AND-
(2) Patient is not receiving Zeposia in combination with a targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz), Olumiant
(baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab),
Skyrizi (risankizumab), Stelara (ustekinumab), Tremfya (guselkumab), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Zeposia [package insert]. Summit, NJ: Celegene Corporation; August 2024.
Program Prior Authorization/Notification – Zeposia (ozanimod)
Change Control
12/2021 New program.
12/2022 Annual review. Added Rinvoq as JAK inhibitor example. Added state
mandate footnote.
12/2023 Annual review. Updated not to be used in combination drugs. Updated
reference.
12/2024 Annual review. No change to coverage criteria. Updated examples of
not to be used in combination with no change to clinical intent.
© 2024 UnitedHealthcare Services, Inc.
2